262 results about "Anti obesity" patented technology

Method and apparatus for limiting absorption of food products in specific parts of the digestive system is presented. A gastrointestinal implant device is anchored in the stomach and extends beyond the ligament of Treitz. All food exiting the stomach is funneled through the device. The gastrointestinal device includes an anchor for anchoring the device to the stomach and a flexible sleeve to limit absorption of nutrients in the duodenum. The anchor is collapsible for endoscopic delivery and removal.

A patient is provided with an increased sense of satiety by increasing resistance to the outflow of food from the stomach and through the intestines. Stomach emptying may be slowed with devices implantable within the gastrointestinal tract below the stomach. Implants are preferably removable and can include artificial strictures that may be adjustable to vary the rate of stomach emptying. Slowing gastric emptying may induce satiety for a longer period and may therefore reduce food consumption. Many of the embodiments include intestinal liners or sleeves, but they need not. The resistor concept may be applied to a simple anchor and resistor without a long liner.

A patient is provided with an increased sense of satiety by increasing resistance to the outflow of food from the stomach and through the intestines. Stomach emptying may be slowed with devices implantable within the gastrointestinal tract below the stomach. Implants are preferably removable and can include artificial strictures or apertures that may be adjustable or elastic to vary the rate of stomach emptying. Slowing gastric emptying may induce satiety for a longer period and may therefore reduce food consumption. Many of the embodiments include intestinal sleeves or sleeves, but they need not. The resistor concept may be applied to a simple anchor and resistor without a long sleeve.

The anti-obesity stent includes a tubular structure having outer and inner surfaces and proximal and distal ends. The tubular structure is sized to fit within a duodenum in substantially coaxial relation therewith. The tubular structure is impervious or semi-permeable to digestive substances and chyme within the duodenum. The anti-obesity stent includes a transport structure at least a part of which is coincident with or connected to the outer surface. The transport structure extends to the distal end of the tubular structure. At least one retainer structure is connected to the tubular structure. The retainer structure secures the tubular structure within the duodenum such that the transport structure is positioned to receive digestive fluids from a papilla of Vater on an inner surface of the duodenum. The transport structure provides a conduit for the digestive fluids therein to flow to the distal end.

The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.

The anti-obesity dual stent includes a tubular outer structure within which is located a coaxial tubular inner structure. The outer structure is sized to fit within a duodenum in substantially coaxial relation therewith. The outer and inner structures communicate with the pylorus and papilla of Vater to provide conduits for the chyme and digestive fluid. Alternatively, the anti-obesity dual stent may include a tubular papilla-supplied structure which has a lateral orientation relative to a tubular pylorus-supplied structure. The papilla-supplied and pylorus-supplied structures each are sized to fit longitudinally within the duodenum. The pylorus-supplied and papilla-supplied structures communicate with the pylorus and papilla of Vater to provide conduits for the chyme and digestive fluid.

The present invention is related to powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them and more particularly, anti-obesity food compositions comprising powder or extracts of one or more selected from group consisting of persimmon leaves, buckwheat leaves, Chinese matrimony vine leaves, endive leaves, and a ginseng. The present invention is related to compositions comprising plant extracts or powder to reduce the weight of animals or human, and more particularly, boiling water extracts of persimmon leaves, buckwheat leaves and Chinese matrimony vine leaves and powder of persimmon leaves, buckwheat leaves and Chinese matrimony vine leaves were prepared and administered to animals or human to confirm effects of reduction of their weight and then health foods comprising the extracts or powder are produced wherein the healthy foods have very excellent effects on the reduction of weight of animals or human without side effects, thereby they have prominent effects on healthy food industry.

The present invention provides compositions and crystals of the carboxyltransferase (CT) domain (the C-terminal ˜90 kDa fragment) of various acetyl-CoA carboxylase (ACC) proteins, including yeast, mouse and human ACCs. Further, the present invention provides methods for identifying and designing compounds that can modulate ACC activity. These methods are based, in part, on the X-ray crystallographic structures of the CT domain of yeast ACC, either alone or bound to acetyl-CoA or a CT inhibitor, such as haloxyfop or diclofop or CP-640186. Thus, the present invention relates to the crystal structures of the carboxyltransferase (“CT”) domain of acetyl-CoA carboxylase (“ACC”), and to the use of these structures in the design of anti-obesity compounds, anti-diabetes compounds, antibiotic compounds, herbicide compounds, and in the design of herbicide resistant plants.

The anti-obesity diverter structure includes a laminate structure having papilla-supplied and pylorus-supplied surfaces. The laminate structure is sized to fit longitudinally within a duodenum such that a transverse clearance is provided between the papilla-supplied surface and papilla of Vater. The laminate structure is secured within the duodenum to define papilla-supplied and pylorus-supplied lumens therein. The papilla-supplied lumen receives the digestive fluid from the papilla of Vater, and provides a conduit for the digestive fluid therein. The pylorus-supplied lumen receives the chyme from the pylorus and provides a conduit for the chyme therein. The laminate structure is impervious or semi-permeable to the chyme and digestive fluid.

Disclosed is a novel long-acting glucagon conjugate in which glucagon or its derivative is covalently linked to a polymer carrier via a non-peptide linker, and a pharmaceutical composition comprising the same as an effective ingredient useful for the prevention and treatment of obesity. Since the long-acting glucagon conjugate of the present invention shows improved in vivo durability and stability, when used in combination with an anti-obesity drug, it is possible to induce synergistic effects on the loss of body weight and decrease in food intake without causing any side-effects such as fluctuation in blood glucose level. Accordingly, the long-acting peptide conjugate of the present invention is very effective for the prevention and treatment of obesity.

The anti-obesity flow controller includes a tubular structure which is sized to fit within a duodenum in substantially coaxial relation therewith. The anti-obesity flow controller includes a transport structure which is connected to the tubular structure. The tubular structure is secured within the duodenum such that the transport structure provides a conduit for the digestive fluid to flow from the papilla of Vater to the distal end of the tubular structure. The tubular structure is further secured within the duodenum such that the proximal end of the tubular structure communicates with the pylorus to provide for the chyme therefrom to flow into the lumen of the tubular structure. A controller structure is connected to the inner surface of the tubular structure to change the velocity of the chyme which flows within the lumen from the proximal to distal ends.

An obesity control agent with health-restorative and health-promotional benefits to humans comprising the extract of Chlorophytum species, more particularly, Chlorophytum arundinacceum, is disclosed. The bioactive principles responsible for anti-obesity property have been determined to be mainly due to spirosta-steroidal saponins, spirosta-steroidal alkaloids and galacto-glucan oligosaccharides. Most effective as an obesity control agent is the spirosta-steroidal saponins. Pharmaceutical, nutritional and veterinary use of this inventive composition is also disclosed.

The present invention relates to an anorectic containing a compound having a DGAT inhibitory activity (DGAT1 inhibitory activity) or a prodrug thereof or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention provides an anti-obesity drug which is an anorectic that does not directly act on the central nervous system and is satisfactory in terms of activity, and a therapeutic strategy for preventing or treating obesity.

This invention provides an anorectic or anti-obesity composition comprising a compound of the formula (I):formula (I):a pharmaceutically acceptable salt or solvate thereof,whereinR1 is optionally substituted lower alkyl,Y is —S(O)n- wherein n is 1 or 2, or —CO—,R2 is hydrogen or lower alkyl,R7 is hydrogen or lower alkyl,X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, andZ is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like.

The invention relates to field of natural medicine and medicinal chemistry, in particular to novel pentacyclic triterpene and melbine salt I of the derivative thereof. The salt compound can be used for preparing medicaments curing diabetes mellitus and complicating disease thereof, cerebral ischemia, angiocardiopathy, atherosclerosis, hepatitis, fatty liver and metabolic syndrome or tumour, descendens blood fat drugs and anti-obesity drugs. The invention also relates to the preparation method of the salt compound.

This invention relates to the therapeutic, diagnostic and pharmacogenetic use of nucleic acids and proteins involved in human proteolytical system such as serine and cysteine proteases and their inhibitors and pharmaceutical agents and other therapies affecting these. This invention discloses methods for the treatment and prevention of cardiovascular diseases such as coronary heart disease (CHD), acute myocardial infarction (AMI), chronic CHD, arterial hypertension (HT) and cerebrovascular stroke and metabolic disorders such as the metabolic syndrome (MBO) and obesity and methods for detecting or diagnosing a risk of, or predisposition to the said diseases in a subject, for selecting treatment in a subject and for selecting subjects for studies testing cardiovascular, anti-diabetic and anti-obesity drugs, as well as to transgenic animals.

A method for enhancing glycemic control and / or insulin sensitivity in a human subject having diabetic nephropathy and / or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and / or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and / or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.

This invention provides an anorectic or anti-obesity composition comprising a compound of the formula (I):a pharmaceutically acceptable salt or solvate thereof,whereinR1 is optionally substituted lower alkyl,Y is —S(O)n— wherein n is 1 or 2, or —CO—,R2 is hydrogen or lower alkyl,R7 is hydrogen or lower alkyl,X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, andZ is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like.

Synergistic anti-adipogenic and pro-lipolytic compositions for the prevention and amelioration of adipogenesis and lipolysis mediated diseases, comprising at least two extracts selected from enriched demethylated curcuminoids obtained from Curcuma longa, Moringa oleifera and Murraya koenigii. The anti-adipogenic and pro-lipolytic compositions optionally contain one or more anti-obesic agents. These compositions are useful for preventing anti-inflammatory and free radical mediated diseases.

The present invention is directed to 1,2,3,4,10,10a,-hexahydro-pyrazino[1,2-a]indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R<1 >to R<8 >have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.

The present invention relates to pet foods containing carbohydrates that include high-amylose starch, and an animal or vegetable protein. They are excellent in benefits such as having an anti-obesity effect and do not impair the pet's appetite or food intake.

Co-therapy of an anti-obesity agent, a statin, and a glitazone is disclosed along with fixed combinations thereof. Atorvastatin, rosiglitazone, and orlistat are preferred as the various components. Non-glitazone antidiabetic agents may be optionally added to the therapy and / or to the fixed combination product.

In general, the invention relates to novel bioactive pentapeptides from heat stabilized defatted rice bran having anti-cancer, anti-obesity, anti-Alzheimer and other health-promoting activities proteins. The bioactive pentapeptides can be incorporated into pharmaceutical, nutraceuticals and food compositions having at least the bioactive pentapeptide as an active ingredient.

The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject. The present invention also relates to the use of PGC-1 expression levels to determine the safe dosage range for known or putative respiration uncoupling agents for use as anti-obesity therapeutics. The present invention further relates to methods for identifying new compounds that have respiration uncoupling activity.